



U.S. National Library of Medicine  
National Center for Biotechnology Information

**NLM Citation:** Yu-Wai-Man P, Chinnery PF. Leber Hereditary Optic Neuropathy. 2000 Oct 26 [Updated 2021 Mar 11]. In: Adam MP, Feldman J, Mirzazadeh GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024.  
**Bookshelf URL:** <https://www.ncbi.nlm.nih.gov/books/>



## Leber Hereditary Optic Neuropathy

Synonyms: Leber's Disease, Leber's Hereditary Optic Neuropathy, Leber's Optic Atrophy, Leber's Optic Neuropathy, LHON

Patrick Yu-Wai-Man, BMedSci, MBBS, PhD, FRCPath, FRCOphth<sup>1,2</sup> and Patrick F Chinnery, BMedSci, MBBS, PhD, FRCPath, FRCP, FMedSci<sup>1</sup>

Created: October 26, 2000; Updated: March 11, 2021.

### Summary

#### Clinical characteristics

Leber hereditary optic neuropathy (LHON) typically presents in young adults as bilateral, painless, subacute visual failure. The peak age of onset in LHON is in the second and third decades of life, with 90% of those who lose their vision doing so before age 50 years. Very rarely, individuals first manifest LHON in the seventh and eighth decades of life. Males are four to five times more likely to be affected than females, but neither sex nor mutational status significantly influences the timing and severity of the initial visual loss. Neurologic abnormalities such as postural tremor, peripheral neuropathy, nonspecific myopathy, and movement disorders have been reported to be more common in individuals with LHON than in the general population. Some individuals with LHON, usually women, may also develop a multiple sclerosis-like illness.

#### Diagnosis/testing

The diagnosis of LHON is established in a proband with a consistent clinical history and/or one of three common mitochondrial DNA (mtDNA) pathogenic variants identified on molecular genetic testing.

#### Management

*Treatment of manifestations:* Management of affected individuals remains mostly supportive, and includes provision of visual aids, occupational rehabilitation, and registration with the relevant social services. Idebenone (Raxone®) has been approved for the treatment of LHON by the European Medicines Agency under exceptional circumstances. The current body of evidence indicates some visual benefit in a subgroup of affected individuals treated with idebenone, particularly those treated within the first year of onset of visual loss.

Referral to a cardiologist for individuals with pre-excitation syndrome on EKG is recommended; treatment for symptomatic individuals is per standard practice.

**Author Affiliations:** 1 Department of Clinical Neurosciences University of Cambridge Cambridge, United Kingdom; Email: [py237@cam.ac.uk](mailto:py237@cam.ac.uk); Email: [pfc25@cam.ac.uk](mailto:pfc25@cam.ac.uk). 2 NIHR Biomedical Research Centre Moorfields Eye Hospital & UCL Institute of Ophthalmology London, United Kingdom; Email: [py237@cam.ac.uk](mailto:py237@cam.ac.uk).

Copyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

A multidisciplinary approach for those affected individuals with extraocular neurologic features (ataxia, peripheral neuropathy, nonspecific myopathy, and movement disorders) should be considered to minimize the functional consequences of these complications.

*Agents/circumstances to avoid:* Individuals in whom a LHON-causing mtDNA variant has been identified should be strongly advised not to smoke and to moderate alcohol intake, avoiding binge-drinking episodes. It would be reasonable to avoid exposure to other putative environmental triggers for visual loss, such as head trauma, industrial toxins, and drugs with mitochondrial toxic effects.

## Genetic counseling

LHON is caused by pathogenic variants in mtDNA and is transmitted strictly by maternal inheritance. The mother of a proband usually has the mtDNA pathogenic variant and may or may not have developed visual loss. A male (affected or unaffected) with a primary LHON-causing mtDNA pathogenic variant cannot transmit the variant to any of his offspring. A female (affected or unaffected) with a primary LHON-causing mtDNA variant transmits the variant to all of her offspring. In approximately 60% of families, a history of visual loss affecting maternal relatives is present. Genetic counseling for LHON is complicated by the sex- and age-dependent penetrance of the primary mtDNA LHON-causing pathogenic variants and penetrance can vary markedly in different branches of the same family and between families harboring the same LHON-causing mtDNA pathogenic variant. Once a mtDNA LHON-causing variant in the mother has been identified, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible; however, accurate interpretation of a positive prenatal test result is difficult because the mtDNA mutational load in amniocytes and chorionic villi may not correspond to that of other fetal or adult tissues, and the presence of the mtDNA LHON-causing variant does not predict the occurrence, age of onset, severity, or rate of progression of visual loss.

## Diagnosis

No consensus clinical diagnostic criteria for Leber hereditary optic neuropathy (LHON) have been published.

## Suggestive Findings

Leber hereditary optic neuropathy (LHON) **should be suspected** in individuals with the following ophthalmologic, extraocular, neuroimaging, and biochemical findings and family history.

### Ophthalmologic

- Bilateral, painless subacute visual failure that develops during young adult life
  - Visual acuity is severely reduced to 20/200 or worse in the majority of cases.
  - Visual field testing by kinetic or static perimetry shows an enlarging dense central or centrocecal scotoma.
- Disk hyperemia, edema of the peripapillary retinal nerve fiber layer, retinal telangiectasia, and increased vascular tortuosity

Note: Approximately 20% of affected individuals show no fundal abnormalities in the acute stage.
- Optic disc atrophy
- Optic nerve dysfunction and absence of other retinal diseases on electrophysiologic studies (pattern electroretinogram and visual evoked potentials)

### Extraocular

- Neurologic abnormalities

- Postural tremor
- Peripheral neuropathy
- Movement disorders
- Multiple sclerosis-like illness
- Nonspecific myopathy
- Cardiac arrhythmias

**Neuroimaging.** MRI is often normal, but may reveal white matter lesions and/or a high signal within the optic nerves [Matthews et al 2015].

**Biochemical** studies show respiratory chain defects that are more subtle than those seen in other mitochondrial genetic disorders. The m.3460G>A pathogenic variant in *MT-ND1* is associated with the most severe biochemical phenotype (see Table 1).

**Table 1.** Respiratory Chain Dysfunction in Leber Hereditary Optic Neuropathy

Mitochondrial DNA Variant	In Vitro		In Vivo
	Complex I activity	Respiratory rate <sup>1</sup>	MRS <sup>1</sup>
m.3460G>A	60%-80% less than controls	30%-35%	0%
m.11778G>A	0%-50% less than controls	30%-50%	75%
m.14484T>C	0%-65% less than controls	10%-20%	50%

See references in Yu-Wai-Man et al [2002].

MRS = magnetic resonance spectroscopy

1. % of decrease relative to controls

**Family history** is consistent with maternal inheritance (e.g., affected females transmit the disorder to all offspring; affected males do not transmit the disorder). Absence of a known family history does not preclude the diagnosis.

## Establishing the Diagnosis

The diagnosis of LHON **is established** in a proband with the ocular manifestations listed in Suggestive Findings **and/or** by one of three common mtDNA pathogenic variants identified by molecular genetic testing (see Table 2).

Note: Identification of a mtDNA variant of uncertain significance does not by itself establish or rule out the diagnosis of this disorder.

Molecular genetic testing approaches can include a combination of **gene-targeted testing** methods (i.e., targeted mtDNA analysis for pathogenic variants, multigene panel, and complete mtDNA sequencing).

### Step 1

**Targeted mtDNA analysis for pathogenic variants.** Targeted analysis for the three common mtDNA pathogenic variants observed in approximately 90% of individuals with LHON should be performed first.

- m.3460G>A in *MT-ND1*
- m.11778G>A in *MT-ND4*, present in 60%-70% of affected individuals of northern European descent and approximately 90% of affected individuals of Asian descent [Mackey et al 1996, Mashima et al 1998, Jia et al 2006]
- m.14484T>C in *MT-ND6*, the predominant variant among individuals of French Canadian descent due to a founder effect [Mackey et al 1996, Macmillan et al 1998, Chinnery et al 2001, Yu-Wai-Man et al 2003]

## Step 2

A **mitochondrial disease multigene panel** that includes the mitochondrial genes that encode subunits of NADH dehydrogenase (*MT-ND1*, *MT-ND2*, *MT-ND3*, *MT-ND4*, *MT-ND4L*, *MT-ND5*, and *MT-ND6*) known to cause LHON, is most likely to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this *GeneReview*. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.

For an introduction to multigene panels click [here](#). More detailed information for clinicians ordering genetic tests can be found [here](#).

## Step 3

**Complete mtDNA sequencing** may be considered if use of targeted testing and/or a multigene panel did not identify a pathogenic variant, clinical suspicion of LHON remains high, and there is no evidence of paternal transmission.

**Table 2.** Molecular Genetic Testing Used in Leber Hereditary Optic Neuropathy

Gene <sup>1</sup>	Proportion of LHON Attributed to Pathogenic Variants in Gene	Proportion of Pathogenic Variants <sup>2</sup> Detected by Method		
		Targeted analysis for pathogenic variants	Sequence analysis <sup>3</sup>	Gene-targeted deletion/duplication analysis <sup>4</sup>
<i>MT-ND4</i> <i>MT-ND6</i> <i>MT-ND1</i>	~90% <sup>5, 6</sup>	See footnote 7.	90% <sup>6</sup>	None reported <sup>6</sup>
Select mitochondrial genes	~10% <sup>6, 8</sup>		10% <sup>6</sup>	None reported <sup>6</sup>

LHON = Leber hereditary optic neuropathy

1. See Table A. Genes and Databases for chromosome locus and protein.

2. See Molecular Genetics for information on allelic variants detected in this gene.

3. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click [here](#).

4. Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

5. Mackey et al [1996]

6. [Mitomap](#)

7. The three most common pathogenic variants are: m.11778G>A (in *MT-ND4*), accounting for 60%-70% of cases among northern European populations [Wallace et al 1988, Mackey et al 1996]; m.14484T>C (in *MT-ND6*), most common among French Canadians as a result of a founder effect [Johns et al 1992a, Macmillan et al 1998]; and m.3460G>A (in *MT-ND1*) [Howell et al 1992].

8. Achilli et al [2012]

**Interpretation of test results.** Heteroplasmy, a mixture of mutated and wild type mtDNA in leukocytes, occurs in approximately 10%-15% of individuals with LHON [Smith et al 1993, Yu-Wai-Man et al 2003].

- Heteroplasmy does not influence the sensitivity of molecular genetic testing for LHON because affected individuals generally have more than 70% mutated mtDNA in leukocytes, which is easily detected by standard techniques.

- It is likely that the level of heteroplasmy may have a bearing on the risk of developing LHON in the asymptomatic individual and on the risk for transmission [Chinnery et al 2001]; however, no rigorous prospective studies have been performed to clarify this possibility.

## Clinical Characteristics

### Clinical Description

Leber hereditary optic neuropathy (LHON) typically presents in young adults as bilateral painless subacute visual failure. The peak age of onset in LHON is in the second and third decades of life, with 95% of those who lose their vision doing so before age 50 years. Very rarely, individuals first manifest LHON in the seventh and eighth decades of life [Dimitriadis et al 2014]. Males are four to five times more likely to be affected than females, but neither sex nor mutational status significantly influences the timing and severity of the initial visual loss.

In the **presymptomatic phase**, fundal abnormalities including peripapillary telangiectatic vessels and variable degrees of retinal nerve fiber layer edema have been previously documented; these can vary with time [Nikoskelainen 1994]. Using optical coherence tomography imaging, thickening of the temporal retinal nerve fiber layer was confirmed in clinically unaffected individuals with a LHON-causing mtDNA pathogenic variant, providing further evidence that the papillomacular bundle is particularly vulnerable in LHON [Savini et al 2005]. On more detailed investigation, some individuals with a LHON-causing mtDNA pathogenic variant can also exhibit subtle impairment of optic nerve function including (1) loss of color vision affecting mostly the red-green system, (2) reduced contrast sensitivity, and (3) subnormal electroretinogram and visual evoked potential [Sadun et al 2006].

Affected individuals are usually entirely asymptomatic until they develop visual blurring affecting the central visual field in one eye (**acute phase**); similar symptoms appear in the other eye within weeks or months, with at least 97% of affected individuals having bilateral involvement within one year [Newman et al 2020]. In 25%-50% of individuals, visual loss is bilateral at onset. The most characteristic feature is an enlarging central or centrocecal scotoma, and as the field defect increases in size and density, visual acuity deteriorates to the level of counting fingers or worse.

Broad generalizations with regard to specific LHON-causing pathogenic variants:

- Variants m.3460G>A and m.11778G>A are associated with significant impairment in visual function and poor visual recovery.
- Variant m.14484T>C is associated with the best long-term visual outcome.

Following the nadir, visual acuity may improve. Note, however, that recovery of visual function in LHON – if it does occur – is usually incomplete.

Reported visual recovery rates in persons with LHON are summarized in Table 3.

In a meta-analysis of 12 retrospective and three prospective studies providing visual function information on 695 affected individuals with the m.11778G>A variant, visual recovery occurred in 14% of affected individuals of all ages and 11% of those age 15 years or older [Newman et al 2020].

**Table 3.** Visual Recovery Rates by Pathogenic Variant in Individuals with Leber Hereditary Optic Neuropathy

Mitochondrial DNA Variant	Visual Recovery <sup>1</sup>	References
m.11778G>A	14% of persons of all ages; 11% of those age ≥15 yrs	Newman et al [2020]
m.14484T>C	37%-64%	Johns et al [1993], Macmillan et al [1998], Spruijt et al [2006]

Table 3. continued from previous page.

Mitochondrial DNA Variant	Visual Recovery <sup>1</sup>	References
m.3460G>A	15%-25% <sup>2</sup>	Johns et al [1992b], Harding et al [1995], Spruijt et al [2006]

1. Different criteria were used to define visual recovery; the range partly reflects this variability.

2. Although published reports would appear to indicate otherwise, the m.3460G>A pathogenic variant is generally accepted among experts as having the worst visual recovery rate [Author, personal communication].

Other predictors of better visual recovery have included an earlier age of onset ( $\leq 12$  years), a subacute presentation with slow visual deterioration, and a relatively large optic disc [Barboni et al 2006, Ramos et al 2009, Majander et al 2017].

The lifetime risk of visual failure by sex and age in individuals with a homoplasmic primary LHON-causing pathogenic variant is summarized in Table 4.

**Table 4.** Lifetime Risk for Visual Failure in Individuals with a Homoplasmic Primary LHON-Causing Mitochondrial DNA Pathogenic Variant by Study

Mitochondrial DNA Pathogenic Variant	Risk of Developing Symptoms		Median Age at Onset (M)	M:F Ratio	Reference
	M	F			
m.3460G>A	32%	15%	20 yrs	4.3:1	Nikoskelainen [1994]
m.3460G>A	49%	28%	22 yrs	1.7:1	Yu-Wai-Man et al [2003]
m.11778G>A	43%	11%	24 yrs	3.7:1	Harding et al [1995]
m.11778G>A	51%	9%	22 yrs	5.1:1	Yu-Wai-Man et al [2003]
m.14484T>C	47%	8%	20 yrs	7.7:1	Macmillan et al [1998]

F = female(s); M = male(s)

The **chronic phase** is characterized by optic atrophy (which typically develops within six weeks of the onset of visual loss), marked thinning of the retinal nerve fiber layer, and a dense central or centrocecal scotoma. Most persons remain severely visually impaired and are within the legal requirements for blind registration [Kirkman et al 2009a].

**Other neurologic features associated with LHON.** Some neurologic abnormalities (e.g., postural tremor, peripheral neuropathy, nonspecific myopathy, movement disorders, Leigh syndrome) have been reported to be common in individuals with LHON [McFarland et al 2007, Martikainen et al 2016].

A multiple sclerosis (MS)-like illness has been reported in association with all three primary mtDNA LHON-causing pathogenic variants (m.3460G>A, m.11778G>A, and m.14484T>C), but with a female bias [Pfeffer et al 2013].

The pattern of visual loss in LHON-MS appears distinct from classic LHON, being marked by recurrent episodes of visual loss that can be associated with ocular pain, but with incomplete visual recovery and progression to legal blindness in half of all affected persons [Pfeffer et al 2013]. In addition to a severe bilateral optic neuropathy, these individuals manifest disseminated central nervous system demyelination, with characteristic periventricular white matter lesions on neuroimaging and unmatched cerebrospinal fluid oligoclonal bands [Bhatti & Newman 1999, Horváth et al 2000, Palace 2009].

**Cardiac conduction defects and LHON.** A Finnish study showed an increased incidence of cardiac arrhythmias secondary to accessory pathways in association with LHON [Nikoskelainen 1994]; this finding has not been replicated in other populations [Bower et al 1992].

## Genotype-Phenotype Correlations

See Clinical Description.

### Penetrance

LHON-causing mtDNA pathogenic variants are characterized by reduced penetrance. An individual can only develop LHON if a pathogenic mtDNA LHON-causing variant is present, but it must be stressed that penetrance can vary markedly in different branches of the same family and between families with the same LHON-causing mtDNA pathogenic variant, which complicates genetic counseling at the individual level.

The two most important risk factors for vision loss are sex and age [Yu-Wai-Man et al 2009].

- **Sex.** Approximately 50% of males and 90% of females with a primary LHON-causing mtDNA pathogenic variant do not develop blindness.
- **Age.** The 95th centile for age at onset in a male is 50 years for all three primary pathogenic variants. Thus, a clinically unaffected male age 50 years has less than a 1/20 chance of losing his vision [Yu-Wai-Man et al 2003] (see also Table 4).

Additional genetic and environmental factors interact with the primary mtDNA pathogenic variant and influence whether an individual ultimately develops optic nerve dysfunction and visual failure.

- **Heteroplasmy.** Many mitochondria (and thus many mtDNA molecules) are present in each cell. Some individuals with a pathogenic LHON-causing mtDNA variant have a mixture of mutated and wild-type species of mtDNA, a finding referred to as heteroplasmy. Heteroplasmy is present in 10%-15% of individuals with a LHON-causing mtDNA variant.
  - In one study, individuals with a m.11778G>A pathogenic variant load of less than 75% in their leukocytes were unaffected [Smith et al 1993].
  - In a retrospective analysis of 17 families heteroplasmic for the m.11778G>A pathogenic variant, males with a mutational load greater than 60% in their leukocytes had a higher frequency of optic neuropathy than those with lower mutational loads [Chinnery et al 2001].

However, testing to quantify the level of heteroplasmy for the purpose of presymptomatic diagnosis (see Genetic Counseling) is limited, as the majority of individuals with a LHON-causing mtDNA variant are homoplasmic.

- **Smoking** has been associated with an increased risk of vision loss in LHON [Kirkman et al 2009b].

### Nomenclature

In the past, LHON was sometimes referred to as Leber hereditary optic neuroretinopathy; this term is outdated and should not be used.

### Prevalence

In northeast England, 1:8,500 individuals were found to have a pathogenic LHON-causing variant; 1:31,000 had experienced visual loss as a result of LHON [Yu-Wai-Man et al 2003, Gorman et al 2015].

Fairly similar figures have been reported in other northern European populations, with a disease prevalence of 1:39,000 in the Netherlands and 1:50,000 in Finland [Spruijt et al 2006, Puomila et al 2007].

## Genetically Related (Allelic) Disorders

Mitochondrial DNA pathogenic variants are responsible for a heterogeneous group of inherited diseases (see [Mitochondrial Disorders Overview](#)) that often cause a progressive neurologic disorder in association with multiorgan involvement (e.g., diabetes mellitus, cardiomyopathy) [McFarland et al 2010, Lightowlers et al 2015].

- In a few families, mtDNA complex I pathogenic variants cause optic atrophy in association with severe neurologic deficits including ataxia, dystonia, and encephalopathy [Jun et al 1994, De Vries et al 1996, Gropman et al 2004, Tarnopolsky et al 2004, Watanabe et al 2006].
- Two mtDNA complex I single-nucleotide variants, m.3376G>A and m.3697G>A, have also been identified in individuals with a LHON-like optic neuropathy and clinical features of [MELAS](#) (mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes) [Blakely et al 2005, Spruijt et al 2007].

## Differential Diagnosis

Unilateral optic nerve involvement in Leber hereditary optic neuropathy (LHON) is exceptionally rare; if it is present, another underlying pathologic process should be actively excluded.

If the ophthalmologic assessment (including an assessment of visual acuity, color vision, visual fields, and electrophysiology) and molecular genetic testing leave any uncertainty about the diagnosis of LHON, further investigations are appropriate to exclude other potentially reversible causes of bilateral optic neuropathy and to allow for the initiation of prompt treatment before visual loss becomes irreversible.

Depending on the clinical presentation and evolution, the following could be considered:

- Autoantibody testing and an infectious or vasculitic screen
- A lumbar puncture to evaluate for unmatched oligoclonal bands when demyelination is suspected or to exclude infection and neoplasia
- Use of the appropriate neuroimaging modality, ideally reviewed with an experienced neuroradiologist

**Acute phase.** A wide range of non-genetic causes of bilateral visual failure must be excluded during the acute phase.

**Chronic phase.** If an individual is only seen at this stage, it can be difficult to exclude other possible causes of optic atrophy, especially if there is no clear maternal family history. In these instances, neuroimaging of the anterior visual pathways is mandatory while awaiting the results of molecular genetic testing.

## Management

An international consensus statement on the clinical and therapeutic management of Leber hereditary optic neuropathy (LHON) has been published [Carelli et al 2017].

## Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with Leber hereditary optic neuropathy (LHON), the evaluations summarized below (if not performed as part of the evaluation that led to the diagnosis) are recommended:

- Measurement of best corrected visual acuity
- Assessment of visual fields with static or kinetic perimetry
- Measurement of retinal nerve fiber layer thickness with optical coherence tomography imaging
- EKG. Although a relatively rare finding, an EKG may reveal a pre-excitation syndrome in both symptomatic and asymptomatic individuals who have a LHON-causing mtDNA variant. Even when



present, such an EKG finding does not necessitate further intervention in the absence of cardiac symptoms.

- Screening for possible associated neurologic complications, which can further compound the visual impairment in individuals with LHON
- Consultation with a medical geneticist, certified genetic counselor, or certified advanced genetic nurse to inform affected individuals and their families about the nature, mode of inheritance, and implications of LHON in order to facilitate medical and personal decision making

## Treatment of Manifestations

Management of affected individuals remains mostly supportive and includes provision of visual aids, occupational rehabilitation, and registration with the relevant local social services.

Idebenone (Raxone<sup>®</sup>) has been approved for the treatment of LHON under exceptional circumstances by the European Medicines Agency [Carelli et al 2017]. The current body of evidence indicates some visual benefit in a subgroup of affected individuals treated with idebenone, in particular those treated within the first year of disease onset [Klopstock et al 2011, Carelli et al 2011, Catarino et al 2020].

There is evidence that increased intraocular pressure could be a risk factor triggering visual loss in individuals at risk for developing LHON. Until further evidence becomes available, it is reasonable to set a lower threshold for initiating treatment for increased intraocular pressure in individuals with a LHON-causing variant given the possible deleterious consequences for mitochondrial function and retinal ganglion cell survival [Thouin et al 2013].

A minority of individuals with LHON develop neurologic features including ataxia, peripheral neuropathy, nonspecific myopathy, and movement disorders [Yu-Wai-Man et al 2016]. This group of affected individuals should be managed by a multidisciplinary team of physicians and allied professionals to minimize the functional consequences of these neurologic complications.

In those individuals who are found to have pre-excitation syndrome on EKG, referral to a cardiologist should be considered. Treatment for symptomatic individuals with pre-excitation syndrome is the same as for the general population.

## Surveillance

Ongoing surveillance of asymptomatic individuals with a LHON-causing mtDNA variant is not necessary; however, they should be advised to seek immediate medical attention if they experience any visual disturbance.

The frequency of follow up for affected individuals varies depending on the individual's personal circumstances and the availability of health care locally.

## Agents/Circumstances to Avoid

Individuals with established LHON-causing mtDNA variants should be strongly advised not to smoke and to moderate their alcohol intake, avoiding binge-drinking episodes [Kirkman et al 2009b].

Although based largely on anecdotal evidence, avoidance of other environmental factors that have been implicated in precipitating visual loss in LHON (e.g., head trauma, industrial toxins, drugs with mitochondrial toxic effects) is reasonable [Yu-Wai-Man et al 2011].

## Evaluation of Relatives at Risk

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

## Therapies Under Investigation

**Gene therapy.** Promising preclinical data based on in vitro and rodent models have resulted in the launch of pivotal clinical trials for affected individuals with the m.11778G>A pathogenic variant. The intervention involves the intravitreal injection of a modified adeno-associated virus (AAV2) vector carrying the replacement *MT-ND4* subunit with a mitochondrial targeting sequence (see [ClinicalTrials.gov](https://www.clinicaltrials.gov)). The published results from ongoing gene therapy programs indicate significant visual improvement in treated individuals beyond what would be expected based on the natural history of LHON [Guy et al 2017, Yuan et al 2020, Yu-Wai-Man et al 2020, Newman et al 2021].

**Hormone therapy.** The marked male bias in LHON could reflect a protective influence of female sex hormones; this hypothesis was recently investigated using LHON cybrid cell lines. Treatment with estrogens was found to reduce reactive oxygen species levels in these LHON cybrids, with increased activity of the antioxidant enzyme superoxide dismutase. These beneficial estrogenic effects translated into more efficient mitochondrial oxidative phosphorylation [Giordano et al 2011, Pisano et al 2015].

**Mitochondrial replacement.** In vitro fertilization (IVF) techniques aimed at preventing the maternal transmission of mtDNA pathogenic variants from mother to child are being developed. Pronuclear transfer and metaphase II spindle transfer are the two approaches that are being investigated, and further experimental work to validate the safety of these IVF strategies is currently ongoing [Tachibana et al 2009, Craven et al 2010, Chinnery et al 2014]. Mitochondrial replacement to prevent the transmission of mtDNA disease with pronuclear transfer has recently been licensed by the Human Fertilisation and Embryology Authority for clinical use in the United Kingdom [Craven et al 2020]. An [ongoing research study](#) will look at the outcome at age 18 months for children in whom this novel reproductive technology was used.

Search [ClinicalTrials.gov](https://www.clinicaltrials.gov) in the US and [EU Clinical Trials Register](https://www.eucr.org/) in Europe for information on clinical studies for a wide range of diseases and conditions.

## Genetic Counseling

*Genetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. —ED.*

## Mode of Inheritance

Leber hereditary optic neuropathy (LHON) is caused by pathogenic variants in mitochondrial DNA (mtDNA) and is transmitted strictly by maternal inheritance.

## Risk to Family Members

### Parents of a proband

- The father of a proband is not at risk of having the mtDNA pathogenic variant.
- The mother of a proband usually has the mtDNA pathogenic variant and may or may not have developed visual loss.
- In approximately 60% of families, a history of visual loss affecting maternal relatives is present.
- Up to 40% of individuals with LHON have no known family history of LHON. The explanation for apparently simplex cases may be absence of a comprehensive and/or reliable family history or, in rare cases, a *de novo* mtDNA pathogenic variant in the proband.

- Maternal testing is not considered necessary for recurrence risk counseling as the mtDNA LHON-causing variant is usually homoplasmic or present at high levels in the proband [Carelli et al 2017].

### Sibs of a proband

- All sibs of a proband will inherit the mtDNA LHON-causing variant and may or may not have symptoms (see **Offspring of a proband**). If the mother of the proband is heteroplasmic for the mtDNA LHON-causing variant, she may transmit a lower level of mutated mtDNA to sibs of the proband, conferring a lower disease risk [Chinnery et al 2001].
- Penetrance can vary markedly between sibs with the same LHON-causing mtDNA pathogenic variant (see Penetrance).

### Offspring of a proband

- A male (affected or unaffected) with a primary LHON-causing mtDNA variant **cannot** transmit the variant to any of his offspring.
- A female (affected or unaffected) with a primary LHON-causing mtDNA variant will transmit the variant to all of her offspring.
- The presence of the mtDNA pathogenic variant does not predict the occurrence, age of onset, severity, or rate of progression of visual loss. See Clinical Description and Penetrance for information regarding the risk to individuals with a primary LHON-causing mtDNA variant of being affected.
- If a female proband is heteroplasmic for the mtDNA LHON-causing variant, she may transmit a lower level of mutated mtDNA to her offspring, conferring a low disease risk [Chinnery et al 2001].

**Other family members.** The risk to other family members depends on the genetic status of the proband's mother: if the proband's mother has a mtDNA pathogenic variant, her sibs and mother are also at risk.

## Related Genetic Counseling Issues

**Penetrance.** Genetic counseling for LHON is complicated by the sex- and age-dependent penetrance of the primary LHON-causing mtDNA variants.

- Large studies have established accurate risks for the m.11778G>A and m.14484T>C pathogenic variants (reviewed in Yu-Wai-Man et al [2009]). Confirming the genetic status of an individual at risk for one of these pathogenic variants who is seeking counseling allows for an accurate estimation of the risks, based on established age- and sex-specific penetrance data (see Clinical Description). Data for the m.3460G>A pathogenic variant are more limited. Similarly, counseling for the other pathogenic variants requires cautious extrapolation.
- The identification of the familial LHON-related pathogenic variant confers a lifetime risk; however, such testing is not useful in predicting the age of onset or the visual outcome in family members. The most important factors determining risk are sex and age (see Clinical Description and Penetrance). For example, a male age 18 years has a lifetime risk of approximately 50% for LHON **after** a positive test result. The risk declines with age but (because loss of sight can occur at any age) never falls to zero. In large, multigenerational LHON pedigrees, these risks were known **before** the advent of molecular genetic testing.
- It must be stressed that the penetrance can vary markedly in different branches of the same family and between families with the same LHON-causing mtDNA pathogenic variant.

### Family planning

- The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.

- It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.

**DNA banking.** Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA from probands in whom a molecular diagnosis has not been confirmed (i.e., the causative genetic alteration/s are unknown).

## Prenatal Testing and Preimplantation Genetic Testing

Once a mtDNA LHON-causing variant in the mother has been identified, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing [Sallevelt et al 2013] are possible.

Accurate interpretation of a positive prenatal test result is difficult for the following reasons:

- The majority of mothers will be homoplasmic for the mtDNA LHON-causing variant. For mothers who are heteroplasmic, the mtDNA mutational load in amniocytes and chorionic villi may not correspond to that of other fetal or adult tissues due to mitotic segregation.
- The presence of the mtDNA LHON-causing variant does not predict the occurrence, age of onset, severity, or rate of progression of visual loss in this mitochondrial genetic disorder. See Clinical Description for information regarding the risk to individuals with a primary LHON-causing mtDNA variant of being affected.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful. For more information, see the National Society of Genetic Counselors [position statement](#) on prenatal testing for adult-onset conditions.

## Resources

*GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click [here](#).*

- **LHON**  
[www.lhon.org](http://www.lhon.org)
- **LHON Society**  
United Kingdom  
[www.lhonsociety.org](http://www.lhonsociety.org)
- **MedlinePlus**  
[Leber hereditary optic neuropathy](#)
- **International Foundation for Optic Nerve Disease (IFOND)**  
NY  
**Phone:** 845-534-8606  
**Email:** ifond@aol.com  
[www.ifond.org](http://www.ifond.org)
- **United Mitochondrial Disease Foundation**  
**Phone:** 888-317-UMDF (8633)  
**Email:** info@umdf.org  
[www.umdf.org](http://www.umdf.org)

- **eyeGENE – National Ophthalmic Disease Genotyping Network Registry**  
**Phone:** 301-435-3032  
**Email:** eyeGENEinfo@nei.nih.gov  
<https://eyegene.nih.gov/>

## Molecular Genetics

*Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.*

**Table A.** Leber Hereditary Optic Neuropathy: Genes and Databases

Gene	Chromosome Locus	Protein	ClinVar
<i>MT-ATP6</i>	Mitochondrion	ATP synthase subunit a	MT-ATP6
<i>MT-CO3</i>	Mitochondrion	Cytochrome c oxidase subunit 3	MT-CO3
<i>MT-CYB</i>	Mitochondrion	Cytochrome b	MT-CYB
<i>MT-ND1</i>	Mitochondrion	NADH-ubiquinone oxidoreductase chain 1	MT-ND1
<i>MT-ND2</i>	Mitochondrion	NADH-ubiquinone oxidoreductase chain 2	MT-ND2
<i>MT-ND3</i>	Mitochondrion	NADH-ubiquinone oxidoreductase chain 3	MT-ND3
<i>MT-ND4</i>	Mitochondrion	NADH-ubiquinone oxidoreductase chain 4	MT-ND4
<i>MT-ND4L</i>	Mitochondrion	NADH-ubiquinone oxidoreductase chain 4L	MT-ND4L
<i>MT-ND5</i>	Mitochondrion	NADH-ubiquinone oxidoreductase chain 5	MT-ND5
<i>MT-ND6</i>	Mitochondrion	NADH-ubiquinone oxidoreductase chain 6	MT-ND6

Data are compiled from the following standard references: gene from [HGNC](#); chromosome locus from [OMIM](#); protein from [UniProt](#). For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click [here](#).

**Table B.** OMIM Entries for Leber Hereditary Optic Neuropathy (View All in OMIM)

516000	COMPLEX I, SUBUNIT ND1; MTND1
516001	COMPLEX I, SUBUNIT ND2; MTND2
516003	COMPLEX I, SUBUNIT ND4; MTND4
516004	COMPLEX I, SUBUNIT ND4L; MTND4L
516005	COMPLEX I, SUBUNIT ND5; MTND5
516006	COMPLEX I, SUBUNIT ND6; MTND6
516020	CYTOCHROME b OF COMPLEX III; MTCYB
516050	CYTOCHROME c OXIDASE III; MTCO3
516060	ATP SYNTHASE 6; MTATP6
535000	LEBER OPTIC ATROPHY

## Molecular Pathogenesis

See [Mitochondrial Disorders Overview](#).

The ocular pathology in Leber hereditary optic neuropathy (LHON) is limited to the retinal ganglion cell layer with sparing of the retinal pigment epithelium and photoreceptor layers. There is marked cell body and axonal degeneration, with associated demyelination, extending to the lateral geniculate bodies. A number of pathologic factors have been implicated, including a reduction in the amount of ATP being produced by the mitochondrial

respiratory chain (Table 1), impaired glutamate transport, and increased levels of reactive oxygen species production, all of which ultimately trigger retinal ganglion cell death via an apoptotic mechanism [Danielson et al 2002, Beretta et al 2004, Zanna et al 2005, Levin 2015, Yu-Wai-Man et al 2017].

Although LHON has a well-defined clinical and molecular genetic phenotype, the pathophysiology is complex and the selective vulnerability of retinal ganglion cells in this mitochondrial disorder remains unexplained [Yu-Wai-Man et al 2011].

Table 5 includes a complete list of mitochondrial DNA variants identified in individuals with LHON [Jurkute et al 2019].

**Table 5.** Mitochondrial DNA Variants Identified in Individuals with LHON

Reference Sequence	Gene	Mitochondrial DNA Variant <sup>1</sup>
NC_012920.1	<i>MT-ND4</i> <sup>2</sup>	<b>m.11778G&gt;A</b> m.11696G>A m.11253T>C
	<i>MT-ND6</i> <sup>2</sup>	<b>m.14484T&gt;C</b> m.14325T>C m.14459G>A <sup>3</sup> m.14729G>A m.14482C>G <sup>3</sup> m.14482C>A <sup>3</sup> m.14495A>G <sup>3</sup> m.14498C>T m.14568C>T <sup>3</sup> m.14596A>T
	<i>MT-ND1</i> <sup>2</sup>	<b>m.3460G&gt;A</b> m.3376G>A m.3635G>A <sup>3</sup> m.3697G>A m.3700G>A <sup>3</sup> m.3733G>A <sup>3</sup> m.4025C>T m.4160T>C <sup>3</sup> m.4171C>A <sup>3</sup>
	<i>MT-ND2</i>	m.4640C>A m.5244G>A
	<i>MT-ND3</i>	m.10237T>C
	<i>MT-ND4L</i>	m.10663T>C <sup>3</sup>
	<i>MT-ND5</i>	m.12811T>C m.12848C>T m.13637A>G m.13730G>A
	<i>MT-ATP6</i>	m.9101T>C
	<i>MT-CO3</i>	m.9804G>A
	<i>MT-CYB</i>	m.14831G>A

From Jurkute et al [2019], Table 1

1. **Bolded** variants are the three most common causes of LHON.

2. Core genes

3. Mitochondrial DNA variants that affect function. They have been identified in at least two independent LHON pedigrees and segregate with affected disease status.

## Chapter Notes

### Revision History

- 11 March 2021 (bp) Comprehensive update posted live
- 23 June 2016 (ma) Comprehensive update posted live
- 19 September 2013 (me) Comprehensive update posted live
- 19 April 2012 (cd/pc) Revision: prenatal testing no longer listed in GeneTests Laboratory Directory; addition to therapies (EPI-743)
- 7 July 2011 (me) Comprehensive update posted live
- 10 March 2008 (me) Comprehensive update posted live
- 3 October 2005 (pc) Revision: mitochondrial gene *MT-ND2* added
- 12 April 2005 (me) Comprehensive update posted live
- 7 March 2003 (me) Comprehensive update posted live
- 14 January 2002 (pc) Author revisions
- 27 August 2001 (pc) Author revisions
- 26 October 2000 (me) Review posted live
- May 2000 (pc) Original submission

## References

### Published Guidelines / Consensus Statements

- Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available [online](#). 2013. Accessed 3-15-21.
- National Society of Genetic Counselors. Position statement on prenatal testing for adult-onset conditions. Available [online](#). 2019. Accessed 3-15-21.

### Literature Cited

- Achilli A, Iommarini L, Olivieri A, Pala M, Hooshar Kashani B, Reynier P, La Morgia C, Valentino ML, Liguori R, Pizza F, Barboni P, Sadun F, De Negri AM, Zeviani M, Dollfus H, Moulignier A, Ducos G, Orssaud C, Bonneau D, Procaccio V, Leo-Kottler B, Fauser S, Wissinger B, Amati-Bonneau P, Torroni A, Carelli V. Rare primary mitochondrial DNA mutations and probable synergistic variants in Leber's hereditary optic neuropathy. *PLoS One*. 2012; 2012;7:e42242. PubMed PMID: 22879922.
- Barboni P, Savini G, Valentino ML, La Morgia C, Bellusci C, De Negri AM, Sadun F, Carta A, Carbonelli M, Sadun AA, Carelli V. Leber's hereditary optic neuropathy with childhood onset. *Invest Ophthalmol Vis Sci*. 2006; 2006;47:5303–9. PubMed PMID: 17122117.
- Beretta S, Mattavelli L, Sala G, Tremolizzo L, Schapira AH, Martinuzzi A, Carelli V, Ferrarese C. Leber hereditary optic neuropathy mtDNA mutations disrupt glutamate transport in cybrid cell lines. *Brain*. 2004;127:2183–92. PubMed PMID: 15342361.
- Bhatti MT, Newman NJ. A multiple sclerosis-like illness in a man harboring the mtDNA 14484 mutation. *J Neuroophthalmol*. 1999;19:28–33. PubMed PMID: 10098545.
- Blakely EL, de Silva R, King A, Schwarzer V, Harrower T, Dawidek G, Turnbull DM, Taylor RW. LHON/MELAS overlap syndrome associated with a mitochondrial MTND1 gene mutation. *Eur J Hum Genet*. 2005;13:623–7. PubMed PMID: 15657614.

- Bower SP, Hawley I, Mackey DA. Cardiac arrhythmia and Leber's hereditary optic neuropathy. *Lancet*. 1992; 1992;339:1427–8. PubMed PMID: 1350847.
- Carelli V, Carbonelli M, de Coo IF, Kawasaki A, Klopstock T, Lagrèze WA, La Morgia C, Newman NJ, Orssaud C, Pott JWR, Sadun AA, van Everdingen J, Vignal-Clermont C, Votruba M, Yu-Wai-Man P, Barboni P. International consensus statement on the clinical and therapeutic management of leber hereditary optic neuropathy. *J Neuroophthalmol*. 2017;37:371–81. PubMed PMID: 28991104.
- Carelli V, La Morgia C, Valentino ML, Rizzo G, Carbonelli M, De Negri AM, Sadun F, Carta A, Guerriero S, Simonelli F, Sadun AA, Aggarwal D, Liguori R, Avoni P, Baruzzi A, Zeviani M, Montagna P, Barboni P. Idebenone treatment in Leber's hereditary optic neuropathy. *Brain*. 2011;134:e188. PubMed PMID: 21810891.
- Catarino CB, von Livonius B, Priglinger C, Banik R, Matloob S, Tamhankar MA, Castillo L, Friedburg C, Halfpenny CA, Lincoln JA, Traber GL, Acaroglu G, Black GCM, Doncel C, Fraser CL, Jakubaszko J, Landau K, Langenegger SJ, Muñoz-Negrete FJ, Newman NJ, Poulton J, Scoppettuolo E, Subramanian P, Toosy AT, Vidal M, Vincent AL, Votruba M, Zarowski M, Zermansky A, Lob F, Rudolph G, Mikazans O, Silva M, Llària X, Metz G, Klopstock T. Real-world clinical experience with idebenone in the treatment of leber hereditary optic neuropathy. *J Neuroophthalmol*. 2020;40:558–65. PubMed PMID: 32991388.
- Chinnery PF, Andrews RM, Turnbull DM, Howell NN. Leber hereditary optic neuropathy: Does heteroplasmy influence the inheritance and expression of the G11778A mitochondrial DNA mutation? *Am J Med Genet*. 2001;98:235–43. PubMed PMID: 11169561.
- Chinnery PF, Craven L, Mitalipov S, Stewart JB, Herbert M, Turnbull DM. The challenges of mitochondrial replacement. *PloS Genet*. 2014;10:e1004315. PubMed PMID: 24762741.
- Craven L, Murphy JL, Turnbull DM. Mitochondrial donation - hope for families with mitochondrial DNA disease. *Emerg Top Life Sci*. 2020;4:151–4. PubMed PMID: 32573698.
- Craven L, Tuppen HA, Greggains GD, Harbottle SJ, Murphy JL, Cree LM, Murdoch AP, Chinnery PF, Taylor RW, Lightowlers RN, Herbert M, Turnbull DM. Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease. *Nature*. 2010;465:82–5. PubMed PMID: 20393463.
- Danielson SR, Wong A, Carelli V, Martinuzzi A, Schapira AH, Cortopassi GA. Cells bearing mutations causing Leber's hereditary optic neuropathy are sensitized to Fas-Induced apoptosis. *J Biol Chem*. 2002;277:5810–5. PubMed PMID: 11741983.
- De Vries DD, Went LN, Bruyn GW, Scholte HR, Hofstra RM, Bolhuis PA, van Oost BA. Genetic and biochemical impairment of mitochondrial complex I activity in a family with Leber hereditary optic neuropathy and hereditary spastic dystonia. *Am J Hum Genet*. 1996;58:703–11. PubMed PMID: 8644732.
- Dimitriadis K, Leonhardt M, Yu-Wai-Man P, Kirkman MA, Korsten A, De Coo IF, Chinnery PF, Klopstock T. Leber's hereditary optic neuropathy with late disease onset: clinical and molecular characteristics of 20 patients. *Orphanet J Rare Dis*. 2014; 2014;9:158. PubMed PMID: 25338955.
- Giordano C, Montopoli M, Perli E, Orlandi M, Fantin M, Ross-Cisneros FN, Caparrotta L, Martinuzzi A, Ragazzi E, Ghelli A, Sadun AA, d'Amati G, Carelli V. Oestrogens ameliorate mitochondrial dysfunction in Leber's hereditary optic neuropathy. *Brain*. 2011;134:220–34. PubMed PMID: 20943885.
- Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL, Feeney C, Horvath R, Yu-Wai-Man P, Chinnery PF, Taylor RW, Turnbull DM, McFarland R. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. *Ann Neurol*. 2015;77:753–9. PubMed PMID: 25652200.
- Gropman A, Chen TJ, Perng CL, Krasnewich D, Chernoff E, Tiffit C, Wong LJ. Variable clinical manifestation of homoplasmic G14459A mitochondrial DNA mutation. *Am J Med Genet A*. 2004;124A:377–82. PubMed PMID: 14735585.



- Guy J, Feuer WJ, Davis JL, Porciatti V, Gonzalez PJ, Koilkonda RD, Yuan H, Hauswirth WW, Lam BL. Gene therapy for Leber hereditary optic neuropathy: low- and medium-dose visual results. *Ophthalmology*. 2017;124:1621–34. PubMed PMID: 28647203.
- Harding AE, Sweeney MG, Govan GG, Riordan-Eva P. Pedigree analysis in Leber hereditary optic neuropathy families with a pathogenic mtDNA mutation. *Am J Hum Genet*. 1995;57:77–86. PubMed PMID: 7611298.
- Horváth R, Abicht A, Shoubridge EA, Karcagi V, Rózsa C, Komoly S, Lochmüller H. Leber's hereditary optic neuropathy presenting as multiple sclerosis- like disease of the CNS. *J Neurol*. 2000;247:65–7. PubMed PMID: 10701903.
- Howell N, McCullough D, Bodis-Wollner I. Molecular genetic analysis of a sporadic case of Leber hereditary optic neuropathy. *Am J Hum Genet*. 1992;50:443–6. PubMed PMID: 1734726.
- Jia X, Li S, Xiao X, Guo X, Zhang Q. Molecular epidemiology of mtDNA mutations in 903 Chinese families suspected with Leber hereditary optic neuropathy. *J Hum Genet*. 2006;51:851–6. PubMed PMID: 16972023.
- Johns DR, Heher KL, Miller NR, Smith KH. Leber's hereditary optic neuropathy. Clinical manifestations of the 14484 mutation. *Arch Ophthalmol*. 1993;111:495–8. PubMed PMID: 8470982.
- Johns DR, Neufeld MJ, Park RD. An ND-6 mitochondrial DNA mutation associated with Leber hereditary optic neuropathy. *Biochem Biophys Res Commun*. 1992a;187:1551–7. PubMed PMID: 1417830.
- Johns DR, Smith KH, Miller NR. Leber's hereditary optic neuropathy. Clinical manifestations of the 3460 mutation. *Arch Ophthalmol*. 1992b;110:1577–81. PubMed PMID: 1444915.
- Jun AS, Brown MD, Wallace DC. A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia. *Proc Natl Acad Sci U S A*. 1994;91:6206–10. PubMed PMID: 8016139.
- Jurkute N, Majander A, Bowman R, Votruba M, Abbs S, Acheson J, Lenaers G, Amati-Bonneau P, Moosajee M, Arno G, Yu-Wai-Man P. Clinical utility gene card for: inherited optic neuropathies including next-generation sequencing-based approaches. *Eur J Hum Genet*. 2019;27:494–502. PubMed PMID: 30143805.
- Kirkman MA, Korsten A, Leonhardt M, Dimitriadis K, De Coo IF, Klopstock T, Griffiths PG, Hudson G, Chinnery PF, Yu-Wai-Man P. Quality of life in patients with Leber hereditary optic neuropathy. *Invest Ophthalmol Vis Sci*. 2009a;50:3112–5. PubMed PMID: 19255150.
- Kirkman MA, Yu-Wai-Man P, Korsten A, Leonhardt M, Dimitriadis K, De Coo IF, Klopstock T, Chinnery PF. Gene-environment interactions in Leber hereditary optic neuropathy. *Brain*. 2009b;132:2317–26. PubMed PMID: 19525327.
- Klopstock T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, Bailie M, Atawan A, Chattopadhyay S, Schubert M, Rummey C, Metz G, Leinonen M, Griffiths PG, Meier T, Chinnery PF. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. *Brain*. 2011;134:2677–86. PubMed PMID: 21788663.
- Levin LA. Superoxide generation explains common features of optic neuropathies associated with cecocentral scotomas. *J Neuroophthalmol*. 2015;35:152–60. PubMed PMID: 25985432.
- Lightowers RN, Taylor RW, Turnbull DM. Mutations causing mitochondrial disease: What is new and what challenges remain? *Science*. 2015;349:1494–9. PubMed PMID: 26404827.
- Mackey DA, Oostra RJ, Rosenberg T, Nikoskelainen E, Bronte-Stewart J, Poulton J, Harding AE, Govan G, Bolhuis PA, Norby S. Primary pathogenic mtDNA mutations in multigeneration pedigrees with Leber hereditary optic neuropathy. *Am J Hum Genet*. 1996;59:481–5. PubMed PMID: 8755941.
- Macmillan C, Kirkham T, Fu K, Allison V, Andermann E, Chitayat D, Fortier D, Gans M, Hare H, Quercia N, Zackon D, Shoubridge EA. Pedigree analysis of French Canadian families with T14484C Leber's hereditary optic neuropathy. *Neurology*. 1998;50:417–22. PubMed PMID: 9484365.

- Majander A, Bowman R, Poulton J, Antcliff RJ, Reddy MA, Michaelides M, Webster AR, Chinnery PF, Votruba M, Moore AT, Yu-Wai-Man P. Childhood-onset Leber hereditary optic neuropathy. *Br J Ophthalmol*. 2017;101:1505–9. PubMed PMID: 28314831.
- Martikainen MH, Ng YS, Gorman GS, Alston CL, Blakely EL, Schaefer AM, Chinnery PF, Burn DJ, Taylor RW, McFarland R, Turnbull DM. Clinical, genetic, and radiological features of extrapyramidal movement disorders in mitochondrial disease. *JAMA Neurol*. 2016;73:668–74. PubMed PMID: 27111573.
- Mashima Y, Yamada K, Wakakura M, Kigasawa K, Kudoh J, Shimizu N, Oguchi Y. Spectrum of pathogenic mitochondrial DNA mutations and clinical features in Japanese families with Leber's hereditary optic neuropathy. *Curr Eye Res*. 1998;17:403–8. PubMed PMID: 9561832.
- Matthews L, Enzinger C, Fazekas F, Rovira A, Ciccarelli O, Dotti MT, Filippi M, Frederiksen JL, Giorgio A, Küker W, Lukas C, Rocca MA, De Stefano N, Toosy A, Yousry T, Palace J. MAGNIMS Network. (2015) MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2015;86:537–42. PubMed PMID: 25053773.
- McFarland R, Chinnery PF, Blakely EL, Schaefer AM, Morris AA, Foster SM, Tuppen HA, Ramesh V, Dorman PJ, Turnbull DM, Taylor RW. Homoplasmy, heteroplasmy, and mitochondrial dystonia. *Neurology*. 2007;69:911–6. PubMed PMID: 17724295.
- McFarland R, Taylor RW, Turnbull DM. A neurological perspective on mitochondrial disease. *Lancet Neurol*. 2010;9:829–40. PubMed PMID: 20650404.
- Newman NJ, Carelli V, Taniel M, Yu-Wai-Man P. Visual outcomes in leber hereditary optic neuropathy patients with the m.11778G>A (MTND4) mitochondrial DNA mutation. *J Neuroophthalmol*. 2020;40:547–57. PubMed PMID: 32969847.
- Newman NJ, Yu-Wai-Man P, Carelli V, Moster ML, Biousse V, Vignal-Clermont C, Sergott RC, Klopstock T, Sadun AA, Barboni P, DeBusk AA, Girmens JF, Rudolph G, Karanjia R, Taniel M, Blouin L, Smits G, Katz B, Sahel JA, et al. Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset. *Ophthalmology*. 2021;128:649–60. PubMed PMID: 33451738.
- Nikoskelainen EK. Clinical picture of LHON. *Clin Neurosci*. 1994;2:115–20.
- Palace J. Multiple sclerosis associated with Leber's Hereditary Optic Neuropathy. *J Neurol Sci*. 2009;286:24–7. PubMed PMID: 19800080.
- Pfeffer G, Burke A, Yu-Wai-Man P, Compston DA, Chinnery PF. Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations. *Neurology*. 2013;81:2073–81. PubMed PMID: 24198293.
- Pisano A, Preziuso C, Iommarini L, Perli E, Grazioli P, Campese AF, Maresca A, Montopoli M, Masuelli L, Sadun AA, d'Amati G, Carelli V, Ghelli A, Giordano C. Targeting estrogen receptor beta as preventive therapeutic strategy for Leber's hereditary optic neuropathy. *Hum Mol Genet*. 2015;24:6921–31. PubMed PMID: 26410888.
- Puomila A, Hamalainen P, Kivioja S, Savontaus ML, Koivumaki S, Huoponen K, Nikoskelainen E. Epidemiology and penetrance of Leber hereditary optic neuropathy in Finland. *Eur J Hum Genet*. 2007;15:1079–89. PubMed PMID: 17406640.
- Ramos CV, Bellusci C, Savini G, Carbonelli M, Berezovsky A, Tamaki C, Cinoto R, Sacai PY, Moraes-Filho MN, Miura HM, Valentino ML, Iommarini L, De Negri AM, Sadun F, Cortelli P, Montagna P, Salomao SR, Sadun AA, Carelli V, Barboni P. Association of optic disc size with development and prognosis of Leber's hereditary optic neuropathy. *Invest Ophthalmol Vis Sci*. 2009;50:1666–74. PubMed PMID: 19098324.
- Sadun AA, Salomao SR, Berezovsky A, Sadun F, Denegri AM, Quiros PA, Chicani F, Ventura D, Barboni P, Sherman J, Sutter E, Belfort R Jr, Carelli V. Subclinical carriers and conversions in Leber hereditary optic neuropathy: a prospective psychophysical study. *Trans Am Ophthalmol Soc*. 2006;104:51–61. PubMed PMID: 17471325.

- Sallevelt SC, Dreesen JC, Drüsedau M, Spierts S, Coonen E, van Tienen FH, van Golde RJ, de Coo IF, Geraedts JP, de Die-Smulders CE, Smeets HJ. Preimplantation genetic diagnosis in mitochondrial DNA disorders: challenge and success. *J Med Genet.* 2013;50:125–32. PubMed PMID: 23339111.
- Savini G, Barboni P, Valentino ML, Montagna P, Cortelli P, De Negri AM, Sadun F, Bianchi S, Longanesi L, Zanini M, Carelli V. Retinal nerve fiber layer evaluation by optical coherence tomography in unaffected carriers with Leber's hereditary optic neuropathy mutations. *Ophthalmology.* 2005;112:127–31. PubMed PMID: 15629832.
- Smith KH, Johns DR, Heher KL, Miller NR. Heteroplasmy in Leber's hereditary optic neuropathy. *Arch Ophthalmol.* 1993;111:1486–90. PubMed PMID: 8240102.
- Spruijt L, Kolbach DN, de Coo RF, Plomp AS, Bauer NJ, Smeets HJ, de Die-Smulders CE. Influence of mutation type on clinical expression of Leber hereditary optic neuropathy. *Am J Ophthalmol.* 2006;141:676–82. PubMed PMID: 16564802.
- Spruijt L, Smeets HJ, Hendrickx A, Bettink-Remeijer MW, Maat-Kievit A, Schoonderwoerd KC, Sluiter W, de Coo IF, Hintzen RQ. A MELAS-associated ND1 mutation causing leber hereditary optic neuropathy and spastic dystonia. *Arch Neurol.* 2007;64:890–3. PubMed PMID: 17562939.
- Tachibana M, Sparman M, Sritanaudomchai H, Ma H, Clepper L, Woodward J, Li Y, Ramsey C, Kolotushkina O, Mitalipov S. Mitochondrial gene replacement in primate offspring and embryonic stem cells. *Nature.* 2009;461:367–72. PubMed PMID: 19710649.
- Tarnopolsky MA, Baker SK, Myint T, Maxner CE, Robitaille J, Robinson BH. Clinical variability in maternally inherited leber hereditary optic neuropathy with the G14459A mutation. *Am J Med Genet A.* 2004;124A:372–6. PubMed PMID: 14735584.
- Thouin A, Griffiths PG, Hudson G, Chinnery PF, Yu-Wai-Man P. Raised intraocular pressure as a potential risk factor for visual loss in leber hereditary optic neuropathy. *PLoS One.* 2013;8:e63446. PubMed PMID: 23667621.
- Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, Elsas LJ, Nikoskelainen EK. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. *Science.* 1988;242:1427–30. PubMed PMID: 3201231.
- Watanabe M, Mita S, Takita T, Goto Y, Uchino M, Imamura S. Leber's hereditary optic neuropathy with dystonia in a Japanese family. *J Neurol Sci.* 2006;243:31–4. PubMed PMID: 16380132.
- Yuan J, Zhang Y, Liu H, Wang D, Du Y, Tian Z, Li X, Yang S, Pei H, Wan X, Xiao S, Song L, Xiao X, Sun J, Wang Z, Li B. Seven-year follow-up of gene therapy for Leber's hereditary optic neuropathy. *Ophthalmology.* 2020;127:1125–7. PubMed PMID: 32284191.
- Yu-Wai-Man P, Griffiths PG, Brown DT, Howell N, Turnbull DM, Chinnery PF. The epidemiology of Leber hereditary optic neuropathy in the North East of England. *Am J Hum Genet.* 2003;72:333–9. PubMed PMID: 12518276.
- Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies. *Prog Retin Eye Res.* 2011;30:81–114. PubMed PMID: 21112411.
- Yu-Wai-Man P, Griffiths PG, Hudson G, Chinnery PF. Inherited mitochondrial optic neuropathies. *J Med Genet.* 2009;46:145–58. PubMed PMID: 19001017.
- Yu-Wai-Man P, Newman NJ, Carelli V, Moster ML, Biousse V, Sadun AA, Klopstock T, Vignal-Clermont C, Sergott RC, Rudolph G, La Morgia C, Karanjia R, Taiel M, Blouin L, Burguière P, Smits G, Chevalier C, Masonson H, Salermo Y, Katz B, Picaud S, Calkins DJ, Sahel JA. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. *Sci Transl Med.* 2020;12:eaaz7423. PubMed PMID: 33298565.

- Yu-Wai-Man P, Soiferman D, Moore DG, Burté F, Saada A. Evaluating the therapeutic potential of idebenone and related quinone analogues in Leber hereditary optic neuropathy. *Mitochondrion*. 2017;36:36–42. PubMed PMID: 28093355.
- Yu-Wai-Man P, Turnbull DM, Chinnery PF. Leber hereditary optic neuropathy. *J Med Genet*. 2002;39:162–9. PubMed PMID: 11897814.
- Yu-Wai-Man P, Votruba M, Burté F, La Morgia C, Barboni P, Carelli V. A neurodegenerative perspective on mitochondrial optic neuropathies. *Acta Neuropathol*. 2016;132:789–806. PubMed PMID: 27696015.
- Zanna C, Ghelli A, Porcelli AM, Martinuzzi A, Carelli V, Rugolo M. Caspase-independent death of Leber's hereditary optic neuropathy cybrids is driven by energetic failure and mediated by AIF and Endonuclease G. *Apoptosis*. 2005;10:997–1007. PubMed PMID: 16151635.

## License

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<http://www.genereviews.org/>) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the [GeneReviews® Copyright Notice and Usage Disclaimer](#). No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the [GeneReviews® Copyright Notice and Usage Disclaimer](#).

For questions regarding permissions or whether a specified use is allowed, contact: [admasst@uw.edu](mailto:admasst@uw.edu).